KEGG   NETWORK: N10008Help
Entry
N10008                      Network                                

Name
Kinase inhibitor to MEK downstream of BRAF mutation
Definition
[BRAF*->MEK] (Trametinib,Cobimetinib,Binimetinib) -| MEK
  Expanded
[N00013] (D10176,D10615,D10604) -| (5604,5605)
Class
nt06210 ERK signaling
nt06268 Melanoma
nt06274 Thyroid cancer
Type
Drug target
Gene
673  BRAF; B-Raf proto-oncogene, serine/threonine kinase
5604  MAP2K1; mitogen-activated protein kinase kinase 1
5605  MAP2K2; mitogen-activated protein kinase kinase 2
Variant
673v1  BRAF mutation
Perturbant
D10176  Trametinib dimethyl sulfoxide
D10615  Cobimetinib fumarate
D10604  Binimetinib
Reference
  Authors
Jing J, Greshock J, Holbrook JD, Gilmartin A, Zhang X, McNeil E, Conway T, Moy C, Laquerre S, Bachman K, Wooster R, Degenhardt Y
  Title
Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.
  Journal
Mol Cancer Ther 11:720-9 (2012)
DOI:10.1158/1535-7163.MCT-11-0505
Reference
  Authors
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D
  Title
Improved survival with MEK inhibition in BRAF-mutated melanoma.
  Journal
N Engl J Med 367:107-14 (2012)
DOI:10.1056/NEJMoa1203421
LinkDB All DBs

DBGET integrated database retrieval system